David Gerber is an Oncology physician. ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2201 Inwood Rd Seay Biomedical Building 2nd Floor
Dallas, TX 75390
Telephone
214-645-4673Registry record last updated 29 May 2019.
Clinical trials
- Cancer Clinical Trials Financial Reimbursement Program
Sponsor: University of Texas Southwestern Medical Center
- Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
Sponsor: David E Gerber
- Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
Sponsor: University of Texas Southwestern Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year202511 payments$10,525openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
32.4%Kinase inhibitor32.4%Tagrisso74%Erlotinib Hcl26%Part D<11 patientsNervous system
23.2%Phenothiazine14.1%Prochlorperazine Maleate100%Part D≥12 patientsAtypical Antipsychotic9.2%Olanzapine100%Part D<11 patientsSensory organs
17.6%Corticosteroid17.6%Dexamethasone100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- UT Southwestern NCI National Clinical Trials Network LAPS
Ut Southwestern Medical Center
FY2026$923,608UG1CA233302 - UT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Funded Extension Supplement YR6
Ut Southwestern Medical Center
FY2025$697,907UG1CA233302 - TCR-antigen foundation model to empower TCR-based diagnostics and therapeutics
University of Tx Md Anderson Can Ctr
FY2025$528,157R01AI192499
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”